Home > Medical Research Archives > Issue 149 > The impact of neoadjuvant immune checkpoint inhibitors on kidney cancer and bladder cancer surgeries: a systematic review
![](https://esmed.org/wp-content/uploads/2022/12/MRA-cover-150x150.png)
Published in the Medical Research Archives
Jun 2024 Issue
The impact of neoadjuvant immune checkpoint inhibitors on kidney cancer and bladder cancer surgeries: a systematic review
Published on Jun 24, 2024
DOI
Abstract
Background: the neoadjuvant use of immune checkpoint inhibitors (ICIs) in patients with kidney cancer and bladder cancer is controversial, and there are reports suggesting increased difficulties in surgeries in these settings.
Aims: we performed a systematic review using PRISMA guidelines methodology to analyze pertinent literature available up to January 05, 2024 in PubMed, updating our previously published systematic review on the subject.
Results: we have selected 25 publications for the neoadjuvant use of different immune checkpoint inhibitors before nephrectomies for kidney cancer and seven publications concerning the neoadjuvant use of immune checkpoint inhibitors before cystectomies for bladder cancer. Reports of additional surgical difficulties were noted in 6/25 reports for kidney cancer and 0/7 reports for bladder cancer.
Conclusions: in the setting of neoadjuvant immune checkpoint inhibitors, a minority of cases of nephrectomies may be challenging due to inflammatory changes to the surrounding tissues, which may require more experienced surgeons. Neoadjuvant immune checkpoint inhibitors do not seem to pose additional surgical difficulties in cystectomies for the treatment of bladder cancer.
Author info
Author Area
Have an article to submit?
Submission Guidelines
Submit a manuscript
Become a member